Deep brain stimulation in late stage Parkinson's disease: A retrospective cost analysis in Germany

Journal of Neurology

Volumn 252, Issue 2, 2005, Pages 218-223

  Meissner, Wassilios ^c   Schreiter, Doreen ^c   Volkmann, Jens ^a,b   Trottenberg, Thomas ^c   Schneider, Gerd Helge ^c   Sturm, Volker ^d   Deuschl, Guenther ^a   Kupsch, Andreas ^c  

^a UNIVERSITY OF KIEL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cost effectiveness; Deep brain stimulation; Parkinson's disease; Subthalamic nucleus

Indexed keywords

AMANTADINE; APOMORPHINE; BUDIPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN SURGERY; BUDGET; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; ELECTRODE; GERMANY; HUMAN; MEDICAL DECISION MAKING; MOTOR ACTIVITY; PARKINSON DISEASE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBTHALAMIC NUCLEUS;

ANALYSIS OF VARIANCE; COSTS AND COST ANALYSIS; DEEP BRAIN STIMULATION; DRUG THERAPY; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RETROSPECTIVE STUDIES; STATISTICS; TREATMENT OUTCOME;

EID: 15244357008     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-005-0640-3     Document Type: Article

References (22)

1. Benabid AL, Pollak P (2000) Cost assessment of functional neurosurgery for abnormal movement by stimulation of the basal nuclei, particularly the subthalamic nucleus. Rev Neurol (Paris) 156(Suppl 2)Pt 2:270-273
2. Blumenschein K, Johannesson M (1996) Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy 36:155-166
3. Bundesverband der pharmazeutischen Industrie, Rote Liste, Rote Liste Verlag, Weinheim, 2002
4. Burchiel KJ, Anderson VC, Favre J, Hammerstad JP (1999) Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 45:1375-1382
5. Dodel RC, Berger K, Oertel WH (2001) Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 19:1013-1038
6. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1236-1239
7. Fahn S, Elton RL (1987) Committee MotUD: Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD (eds) Recent developments in Parkinson's disease. Florham Park, Macmillan Health Care, pp 153-164
8. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, Lebas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349:1925-1934
9. Krack P, Limousin P, Benabid AL, Pollak P (1997) Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet 350:1676
10. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE (1998) Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51:850-855
11. Lang AE, Widner H (2002) Deep brain stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 17(Suppl 3):S94-S101
12. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481
13. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339:1105-1111
14. Mandelblatt JS, Fryback DG, Weinstein MC, Russell LB, Gold MR (1997) Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med 12:551-558
15. Marsden CD, Parkes JD, Quinn N (1982) Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S (eds) Neurology 2: Movement Disorders. London, Butterworth Scientific, pp 96-122
16. Meissner W, Hill M, Tison F, Gross CE, Bezard E (2004) Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci 25:249-253
17. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53: 85-90
18. Rodriguez-Oroz MC, Gorospe A, Guridi J, Ramos E, Linazasoro G, Rodriguez-Palmero M, Obeso JA (2000) Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology 55:S45-S51
19. Shils JL, Miravite J, Tagliati M, Alterman RL (2002) Economic impact of the reduction in medication requirements after STN deep brain stimulation in Parkinson's disease. Mov Disord 17(Suppl 5):S194
20. Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, Gerstner A, Berger K, Hellwig D, Deuschl G, Freund HJ, Oertel WH, Dodel RC (2002) Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 249:759-766
21. Tomaszewski KJ, Holloway RG (2001) Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 57:663-671
22. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V (2001) Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 56:548-551